Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review

References

• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, Phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/s0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–1268. doi:10.1016/j.jaad.2020.03.132
   PubMed Web of Science ®Google Scholar
• Bui AN, Singer S, Hirner J, et al. De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: a retrospective analysis. J Am Acad Dermatol. 2021;84(3):864–869. doi:10.1016/j.jaad.2020.10.054
   PubMed Web of Science ®Google Scholar
• Lin WH, Lee KY, Lee WR, Shih YH. Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment. J Dermatol. 2020;47(9):1041–1045. doi:10.1111/1346-8138.15371
   PubMed Web of Science ®Google Scholar
• Rousseau PM, Raimbourg J, Robert M, Dansette D, Dréno B, Peuvrel L. First case of cutaneous sarcoidosis within tattoos under durvalumab. Int J Dermatol. 2019;58(9):e168–e170. doi:10.1111/ijd.14484
   PubMed Web of Science ®Google Scholar
• Coustal C, Du Thanh A, Roubille F, Assenat E, Maria ATJ. Rare cutaneous toxicity of immune checkpoint inhibitors: a case of durvalumab-induced dermatomyositis. Eur J Cancer. 2021;155:25–27. doi:10.1016/j.ejca.2021.06.031
   PubMed Web of Science ®Google Scholar
• Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164(3):465–472. doi:10.1111/j.1365-2133.2010.10110.x
   PubMed Web of Science ®Google Scholar
• Bui AN, Hirner J, Singer SB, et al. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. Clin Exp Dermatol. 2021;46(2):328–337. doi:10.1111/ced.14449
   PubMed Web of Science ®Google Scholar
• González García A, Sifuentes Giraldo WA, Grillo Fernández E, Zea Mendoza A. Subacute cutaneous lupus erythematosus associated with pemetrexed plus Carboplatin chemotherapy. J Clin Rheumatol. 2014;20(8):449–450. doi:10.1097/rhu.0000000000000183
   PubMed Web of Science ®Google Scholar
• Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007;33(1–2):85–106. doi:10.1007/s12016-007-0031-x
   PubMed Web of Science ®Google Scholar
• Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152(10):1128–1136. doi:10.1001/jamadermatol.2016.2226
   PubMed Web of Science ®Google Scholar
• Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2(2):85–95. doi:10.1038/nri724
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Limtong P, Ngamjanyaporn P, Suchonwanit P. Trichoscopic signs in dermatomyositis, systemic lupus erythematosus, and systemic sclerosis: a comparative study of 150 patients. Dermatology. 2021;1–11. doi:10.1159/000520297
   Web of Science ®Google Scholar
• Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol. 2013;149(9):1071–1075. doi:10.1001/jamadermatol.2013.4957
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Ploydaeng M, Pakornphadungsit K, Mekwilaiphan T, Vachiramon V, Kanokrungsee S. The behavior, attitude, and knowledge towards photoprotection in patients with cutaneous/systemic lupus erythematosus: a comparative study with 526 patients and healthy controls. Photochem Photobiol Sci. 2020;19(9):1201–1210. doi:10.1039/d0pp00073f
   PubMed Web of Science ®Google Scholar
• Hasan Ali O, Bomze D, Ring SS, et al. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol. 2020;82(4):854–861. doi:10.1016/j.jaad.2019.08.045
   PubMed Web of Science ®Google Scholar
• Seree-aphinan C, Chanprapaph K, Rattanakaemakorn P, et al. Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants. Front Med. 2021;8:769845. doi:10.3389/fmed.2021.769845
   PubMed Web of Science ®Google Scholar
• Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583–589. doi:10.1093/annonc/mdw640
   PubMed Web of Science ®Google Scholar
• Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Melanoma Res. 2019;29(3):338–341. doi:10.1097/cmr.0000000000000587
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Pomsoong C, Kositkuljorn C, Suchonwanit P. Intramuscular corticosteroid therapy in the treatment of alopecia areata: a time-to-event analysis. Drug Des Devel Ther. 2022;16:107–116. doi:10.2147/DDDT.S342179
   PubMed Web of Science ®Google Scholar
• Ogawa-Momohara M, Muro Y, Goto K, et al. Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab. J Dermatol. 2020;47(6):e217–e219. doi:10.1111/1346-8138.15316
   PubMed Web of Science ®Google Scholar
• Chasset F, Bouaziz JD, Costedoat-Chalumeau N, Francès C, Arnaud L. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol. 2017;177(1):188–196. doi:10.1111/bjd.15312
   PubMed Web of Science ®Google Scholar
• Zitouni NB, Arnault JP, Dadban A, Attencourt C, Lok CC, Chaby G. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res. 2019;29(2):212–215. doi:10.1097/cmr.0000000000000536
   PubMed Web of Science ®Google Scholar
• Liu RC, Sebaratnam DF, Jackett L, Kao S, Lowe PM. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J Dermatol. 2018;59(2):e152–e154. doi:10.1111/ajd.12681
   PubMed Web of Science ®Google Scholar
• Kosche C, Owen JL, Choi JN. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab. Dermatol Online J. 2019;25(10). doi:10.5070/D32510045821
   Google Scholar
• Marano AL, Clarke JM, Morse MA, et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br J Dermatol. 2019;181(3):580–583. doi:10.1111/bjd.17245
   PubMed Web of Science ®Google Scholar
• Takeda K, Nakano K, Udagawa S, et al. Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitor. Rheumatology. 2021. doi:10.1093/rheumatology/keab670
   PubMed Web of Science ®Google Scholar
• Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139(1):45–49. doi:10.1001/archderm.139.1.45
   PubMedGoogle Scholar